VFA
MRTX

Values First Advisors’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Values First Advisors’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,412
Closed -$52.5K – 360
2023
Q1 		$52.5K Buy
+1,412
New +$63.5K 0.03% 188

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Values First Advisors's MRTX Position: Q2 2023 in Review

Values First Advisors sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2023, closing a stake of 1,412 shares — an estimated $52.5K sold.

Values First Advisors first reported a position in MRTX in Q1 2023 and held it in 1 quarter. The position peaked at $52.5K in Q1 2023. 207 funds tracked by Wall St. Rank hold MRTX as of Q2 2023.

  • Values First Advisors reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Values First Advisors sold 1,412 Mirati Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $52.5K.
  • Values First Advisors first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2023 and held it in 1 quarter.
  • Values First Advisors's Mirati Therapeutics, Inc. Common Stock position peaked at $52.5K in Q1 2023.
  • 207 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Values First Advisors's 13F filing for Q2 2023, filed 2 Aug 2023.